// App-Quantinova.ai

PB0793 : Preference for ravulizumab over eculizumab: a real-world patient preference and life impact study on the treatment of atypical hemolytic uremic syndrome

Researchers

Presenter

  • T. Mauch

Principal Investigators

  • S. Cataland

  • S. Chaturvedi

  • A. Java

  • T. Pham

  • T. Symonds

  • I. Tomazos

  • Y. Wang

Medical Centers

  • University of Nebraska - Omaha Omaha NE United States

  • Clinical Outcomes Solutions, LLC (at the time of the study), Chicago, Illinois, United States

  • 6Wexner Medical Center At The Ohio State University Columbus OH United States

  • John Hopkins University, Baltimore, Maryland, United States

  • Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, United States

  • Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, United States

  • Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States

  • Georgia Cancer Specialists/Northside Hospital Cancer Institute, Atlanta, Georgia, United States

  • Clinical Outcomes Solutions, Folkestone, United Kingdom

  • Clinical Outcomes Solutions, LLC, Chicago, Illinois, United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Blood/haematological Diseases

Disease

  • Atypical hemolytic uremic syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved